IL-NIELSENIQ
13.5.2024 18:20:35 CEST | Business Wire | Press release
NielsenIQ (NIQ), the world leader in measurement and data analytics, is excited to announce that ‘NIQ Ask Arthur’- a groundbreaking GenAI-driven tool—has been integrated into NIQ Discover. This transformative solution offers AI-guided global search and personalized recommendations, streamlining data analysis and facilitating informed decision-making. Launching “NIQ Ask Arthur” marks an important milestone for NIQ Labs. Positioned as an innovation powerhouse, NIQ Labs is ready to accelerate the future of innovation by solving client problems and uncovering new pathways to growth. Coupled with investments, NIQ Labs taps into an extensive array of data assets, employing intuitive business intelligence tools and predictive analytics driven by generative AI (GenAI) and authoritative data science pioneering the next era of inventive products.
With conversational AI features, ‘NIQ Ask Arthur’ empowers users to delve deeper into datasets, revolutionizing data-driven choices and showcasing NielsenIQ's commitment to cutting-edge analytics.
NIQ Discover, a state-of-the-art data visualization solution, accelerates access to insights for CPG manufacturers and retailers. It creates fresh, user-friendly pathways to insights, leveraging the power of on-demand data across multiple data sets. NIQ Discover is designed to help CPG manufacturers and retailers get meaningful insights faster, and measure and track what’s most important to their business within a single, centralized platform.
NIQ Ask Arthur in NIQ Discover enables enhanced insights discovery, so users can efficiently uncover valuable information, enriching the brand story and democratizing data access. Current and new users can uncover meaningful information, trends, and patterns that may otherwise go unnoticed, leading them to the most relevant areas of analysis. At NIQ we provide the Full View™, and we maintain the highest standard of data accuracy and quality. GenAI will help NIQ Discover users decipher diverse formats and tackle complex business questions.
“The vision of leveraging AI to assist in data analysis and storytelling is incredibly powerful. Democratizing access to data and analytics is crucial in helping users make informed decisions and drive innovation. ‘NIQ Ask Arthur’ unlocks the power of analytics on the Discover platform,” says Troy Treangen, Chief Product Officer, NIQ.
NIQ Ask Arthur in Discover enables users to save time by proactively suggesting insights and simplifying data navigation through a seamless, conversational AI-powered experience.
With NIQ’s investment in the cutting edge NIQ Discover platform, combined with our diverse data types and deep industry expertise, NIQ Ask Arthur delivers unparalleled value to clients.
NIQ is best positioned to understand data and the business questions that help brands unravel their story. The company’s agility and rapid deployment strategies have facilitated remarkable technological advancement. In the past year, the NIQ Discover platform witnessed extraordinary growth, surging from 2,500 users in January 2023 to an impressive 40,000 across 71 countries today, showcasing the vast scale of NIQ’s technological expansion. This ability to rapidly deploy technology, enhance user engagement, and establish a global presence underscores NIQ’s unparalleled agility and innovation in the tech industry. These advancements facilitate accelerated insights across diverse industries, channels, and products, driving speed-to-insight at an unprecedented scale to deliver the Full View™.
About NIQ
NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in 95+ countries representing 97% of the world’s GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513168921/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
